LOGIN  |  REGISTER
Assertio
Astria Therapeutics

NEXGEL to Participate in Maxim Group’s Virtual Healthcare Conference on June 20th

June 15, 2023 | Last Trade: US$4.74 0.08 1.72

LANGHORNE, Pa., June 15, 2023 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that Adam Levy, CEO, will participate in a virtual fireside chat with Naz Rahman, CFA, Vice President, Senior Equity Research Analyst, at the Maxim Group Virtual Healthcare Conference being held on June 20th - 22nd.

Maxim Group Fireside Chat Details

Date: June 20, 2023

Presentation Time: 3:30 P.M. ET

Registration: HERE

The conference is being hosted by M-Vest, a division of Maxim. If you would like to schedule a meeting with NEXGEL, please contact your Maxim representative or send an email to This email address is being protected from spambots. You need JavaScript enabled to view it..

About NEXGEL, INC.
NEXGEL is a leading provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL has formulated more than 200 different combinations to bring natural ingredients to gentle skin patches that can be worn for long periods of time with little to no irritation.

Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contacts:
Kelly Knobeck
Director of Consumer Products
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB